<DOC>
	<DOCNO>NCT00038376</DOCNO>
	<brief_summary>The purpose study determine response rate patient T-cell malignancy combination therapy use interferon-alpha ( Roferon ) Isotretinoin ( Accutane ) .</brief_summary>
	<brief_title>Phase II Study Of Roferon Accutane For Patients With T-Cell Malignancies</brief_title>
	<detailed_description>Retinoids show activity T-cell malignancy past study ( isotretinoin etretinate ) overall response rate 60 % . One third responses complete response . Interferon-alpha proven efficacy wide range human malignancy include T-cell lymphoma single agent . A clinical trial need evaluate response rate two agent combine . Interferon normal body protein , make cell exposure virus . It act messenger warn surround cell invasion virus , possibly , cancer cell . Isotretinoin synthetic form Vitamin A effect growth normal cell cancer cell . Participants participate study receive combination alpha-interferon isotretinoin . Alpha-interferon give day initial period 12 week . Participants take drug home , nurse family member participant ( trained UTMDACC ) inject skin ( SQ ) . Isotretinoin give mouth twice day . If participant 's disease show response , alpha-interferon isotretinoin increase . If side effect occur , dose alpha-interferon and/or isotretinoin decrease 50 % . If side effect severe , therapy discontinue . If participant 's disease unresponsive worsens , participant take study treatment recommend . Responding participant place maintenance schedule long respond . Up 60 participant study UT M.D . Anderson Cancer Center test effectiveness drug combination . This investigational study . Alpha-interferon isotretinoin FDA approve commercially available .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>1 . Patients histologic proof incurable Tcell malignancy Hodgkin 's disease , eligible existing/higher priority protocol . Patients Hodgkin 's disease eligible fail least MOPPlike ABVDlike regimen . 2 . Patients receive chemotherapy , immunotherapy , hormonal therapy , radiation therapy within three week entry study must recover acute toxic effect prior therapy . 3 . Patients must life expectancy least 12 week performance status less equal 2 ( Zubrod scale : Appendix A ) . 4 . Patients must sign informed consent indicate aware investigational nature study , keep policy hospital . The approved consent form append protocol . 5 . Patients must measurable evaluable disease . 6 . Patients must great equal 18 year old . 7 . Patients may receive concurrent chemotherapy , immunotherapy , radiotherapy . 8 . Patients adequate hepatic function bilirubin less equal 2.0 mg % , SGPT le equal 4 time upper limit normal . 9 . Patients adequate renal function ( define serum creatinine less equal 2.0 mg % ) . 10 . Patients serum triglyceride level less equal 2.5 time upper limit normal . 11 . Patients may serious intercurrent medical illness . 12 . Patients child bear potential must practice adequate contraception . 13 . Patients eligible regardless extent prior chemotherapy . 1 ) Pediatric Patients 18 year old .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>T-cell lymphoma</keyword>
	<keyword>accutane</keyword>
	<keyword>isotretinoin</keyword>
	<keyword>mycosis fungoides</keyword>
	<keyword>T-cell malignancy</keyword>
</DOC>